Posted: 30 Aug 2014 08:18 AM PDT
An investigational new heart failure drug could be poised to change the face of cardiology based on Hot Line results. The new agent, known as LCZ696, has already been granted Fast Track status by the FDA -- a designation which can expedite the review of new medicines intended to treat serious or life-threatening conditions. Fast Track designation also allows for rolling submission in the US. "To say that we are excited is an understatement. We are absolutely thrilled," said one investigator.
|You are subscribed to email updates from All Top News -- ScienceDaily |
To stop receiving these emails, you may unsubscribe now.
|Email delivery powered by Google|
|Google Inc., 20 West Kinzie, Chicago IL USA 60610|